Evaluation of the Pathobiology of CALR-mutated MPN Cells
ConditionMyeloproliferative Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWake Forest University Health Sciences
About this trial
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Eligibility criteria
Qualifiers
Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
Age ≥ 18 years at the time of enrollment
Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
CALR-positive genetic mutation
Disqualifiers
None
Trial design
Treatments tested in this trial
- Blood Draw
Treatment groups
35 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
Atrium Health Levine Cancer Institute
Collaborator
Brookdale University Hospital Medical Center
Collaborator
Source ClinicalTrials.gov